Opening: Physician Decision-Making Logic
In reproductive genetics clinics, when developing a third-generation IVF (PGT) plan, physicians must clearly explain the accuracy boundaries of the testing technology to patients. This is not about shifting responsibility, but rather acknowledging the objective technical limitations inherent in medical testing. A patient once held a PGT-A report and asked, “This embryo is normal, so there won’t be any problems after transfer, right?” This question directly addresses the true meaning of preimplantation genetic testing accuracy. As a reproductive physician, it is necessary to clarify that a “normal” test report does not mean the embryo is absolutely healthy. Accuracy must be understood from three dimensions: technology type, testing platform, and embryo biological characteristics.
Direct Answer to the Accuracy of Preimplantation Genetic Testing in China
Under standard operating procedures at major Chinese reproductive centers (such as CITIC Xiangya, Peking University Third Hospital, Shanghai Renji Hospital, and the Reproductive Hospital Affiliated to Shandong University), the accuracy of preimplantation genetic testing (PGT) is as follows:
- PGT-A (Aneuploidy Testing): Testing specificity is approximately 95%–98%, and sensitivity is approximately 90%–95%. Compared with birth outcomes or prenatal diagnosis results, the overall concordance rate is between 93% and 96%.
- PGT-M (Monogenic Disease Testing): Combined with family linkage analysis and direct mutation detection, the diagnostic accuracy can reach over 99%, provided that proband and family samples are complete.
- PGT-SR (Structural Rearrangement Testing): The accuracy for detecting balanced translocations, inversions, and other abnormalities is approximately 90%–95%, influenced by breakpoint location and resolution.
These data are derived from published clinical studies and multi-center validation reports, reflecting the current mainstream testing level in the field of assisted reproduction in China. However, accuracy is not a fixed value; it fluctuates depending on biopsy stage, testing platform, embryo mosaicism status, laboratory experience, and other factors.
Why Preimplantation Genetic Testing Accuracy Cannot Reach 100%
Preimplantation genetic testing is essentially a predictive screening tool, not a diagnostic test. Its technical boundaries arise from three levels:
1. Embryo Biological Limitation: Mosaicism
During early embryonic development, cell division can produce cell populations with different genetic compositions—known as mosaicism. Biopsy typically takes 5–10 cells from the trophectoderm of the blastocyst. If these cells happen to come from a normal cell group, while the inner cell mass (which will develop into the fetus) contains abnormal cells, the test results may be biased, and vice versa. Clinical data show that approximately 15%–30% of blastocysts exhibit some degree of mosaicism, which is the primary biological reason why PGT accuracy cannot reach 100%.
2. Testing Technology Resolution
The current mainstream platform—next-generation sequencing (NGS)—can detect chromosomal copy number variations of 5–10 Mb or larger, but microdeletions/microduplications smaller than 5 Mb may be missed. The aCGH platform has a lower resolution, approximately 10 Mb. Additionally, testing platforms have a lower limit for detecting mosaicism; typically, when the mosaicism level is below 20%, it is difficult to reliably distinguish.
3. Biopsy Procedure and Sample Quality
Biopsy timing (cleavage stage vs. blastocyst stage), the number of biopsied cells, DNA amplification efficiency, and laboratory contamination control—each step can affect the reliability of test results. Blastocyst-stage biopsy (days 5–6) has significantly higher accuracy than cleavage-stage biopsy (day 3) due to a larger number of cells and better representativeness.
How Physicians Interpret PGT Results: Clinical Decision-Making Logic
In clinical reproductive medicine, physicians do not treat PGT reports as “absolute truth” but incorporate them into a comprehensive evaluation system:
- “Euploid” Embryo: Indicates that no clear chromosomal copy number abnormalities were found in the tested region, but does not rule out micro-variations smaller than 5 Mb, uniparental disomy (UPD), or other genetic issues outside the testing scope. Prenatal diagnosis (amniocentesis) is still required after transfer for verification.
- “Aneuploid” Embryo: In most cases, accuracy is high, but there is a possibility of false positives (approximately 2%–5%), especially when mosaic embryos are misclassified as euploid or aneuploid.
- “Mosaic” Embryo: This is the most complex clinical scenario. Physicians make a comprehensive judgment based on the mosaicism level, chromosome type, mosaic embryo score, patient age, previous reproductive history, and other factors to decide whether to transfer, and fully inform the patient of the risks.
Comparison of Accuracy Across Different PGT Technologies
The testing platforms commonly used in domestic reproductive centers and their corresponding accuracy data are as follows:
| Test Type | Common Platform | Sensitivity | Specificity |
|---|---|---|---|
| PGT-A (NGS) | Illumina platform, MGI platform | 90%–95% | 95%–98% |
| PGT-A (aCGH) | Agilent platform | 85%–92% | 92%–96% |
| PGT-M (NGS + Linkage Analysis) | Target region capture sequencing | >99% (with complete family data) | >99% |
| PGT-SR (NGS) | Whole-genome low-depth sequencing | 88%–93% | 90%–95% |
Data Note: The ranges above are from clinical validation reports published by more than 5 domestic reproductive centers between 2019 and 2023. Data may vary slightly between centers due to differences in sample size, embryo quality, and operational habits.
Easily Overlooked Details: Mosaicism and Detection Resolution
During consultations, patients most often overlook two technical details:
- Clinical Significance of Mosaicism: A report showing “low-level mosaicism (20% mosaic)” may lead some patients to think “it’s not a big problem.” In reality, after transferring a mosaic embryo, the fetus may exhibit clinical manifestations inconsistent with the mosaicism level because the proportion of mosaicism can change dynamically during development. Currently, there is no unified standard to predict pregnancy outcomes for mosaic embryos.
- Detection Resolution Boundaries: PGT-A cannot detect microdeletions/microduplications smaller than 5 Mb, nor can it detect uniparental disomy, triploidy (partially identifiable), or genetic imprinting abnormalities. This means that a “euploid” embryo still carries an approximately 1%–3% risk of clinically significant genetic issues.
These two details directly affect the understanding of accuracy—a “normal” test report is normal only under specific conditions.
Common Pitfalls: Overinterpretation of PGT Results
Common cognitive misunderstandings in clinical practice include:
- Misunderstanding 1: “A PGT-normal embryo is 100% healthy after transfer.” — In reality, PGT only detects chromosomal copy numbers or specific gene loci; it does not assess embryo developmental potential, metabolic function, or epigenetic status.
- Misunderstanding 2: “If an embryo has been tested by PGT, prenatal diagnosis is unnecessary.” — This is incorrect. PGT is a screening tool; prenatal diagnosis (amniocentesis/chorionic villus sampling) is a confirmatory test, and they cannot replace each other.
- Misunderstanding 3: “If the test result is abnormal, the embryo cannot be transferred.” — Some mosaic embryos or embryos with low-level aneuploidy may still be transferred and result in a healthy live birth after thorough counseling and risk assessment, especially when the patient has no other transferable embryos.
Differences in PGT Accuracy Between China and Other Countries
In terms of technology platforms and operational standards, the PGT testing level at major Chinese reproductive centers is essentially on par with developed countries such as the United States, the United Kingdom, and Spain. Differences are mainly reflected in the following aspects:
- Platform Independence: Chinese centers use both the domestic MGI platform and the imported Illumina platform for NGS. There is no significant difference in PGT-A performance between the two, with the domestic platform offering slightly higher resolution in some metrics.
- Biopsy Experience: The annual number of PGT cycles in China is growing rapidly. Some centers perform over 2,000 blastocyst biopsies per year, with operational proficiency and stability reaching internationally advanced levels.
- Genetic Counseling System: Compared with countries like the United States, China has fewer certified genetic counselors. In some centers, reproductive physicians also handle genetic counseling, which may affect patients’ understanding of accuracy.
- Regulation and Standardization: The application of PGT technology in China is strictly regulated by the National Health Commission, and centers must pass accreditation reviews. However, the implementation of laboratory quality control standards varies across provinces.
Overall, PGT testing at正规 Chinese reproductive centers shows no significant gap in accuracy compared with top international centers. Differences are more pronounced in counseling depth and consistency of quality control.
Frequently Asked Questions About PGT Accuracy
- Q: What is the miscarriage rate after transferring a PGT-A normal embryo?
A: The miscarriage rate is approximately 10%–15%, lower than in non-PGT cycles (20%–25%), but there is still a risk because miscarriage causes are not limited to chromosomal abnormalities; they also include maternal factors, immune factors, and embryo developmental potential. - Q: Is the accuracy of PGT-M higher than that of PGT-A?
A: Yes. PGT-M targets known single-gene loci and, combined with linkage analysis, can achieve an accuracy of over 99%, provided that proband and family samples are complete. PGT-A tests for whole-chromosome aneuploidy, involving more chromosomes and different technical complexity. - Q: Which reproductive center in China has the highest PGT accuracy?
A: There is currently no official ranking. Accuracy is related to the center’s annual biopsy volume, laboratory quality control, and embryo culture standards. It is recommended to choose a reproductive center approved by the National Health Commission with an annual PGT cycle count > 500 for better accuracy assurance. - Q: Is non-invasive prenatal testing (NIPT) still necessary after PGT?
A: Yes. NIPT can detect fetal cell-free DNA and screen for certain chromosomal abnormalities that PGT cannot cover. However, NIPT is also a screening test and cannot replace prenatal diagnosis.
Practitioner Observation: Real Challenges Behind the Accuracy Numbers
As a reproductive physician, several noteworthy phenomena are observed in daily practice:
- Some patients interpret PGT accuracy as a “guarantee of success,” overlooking the weight of the embryo’s own developmental potential. In reality, the implantation rate of euploid embryos is approximately 50%–65%, not 100%.
- Management of mosaic embryos is one of the biggest clinical controversies in the PGT field. Different centers have inconsistent transfer criteria for mosaic embryos, and patients may receive completely different advice from different institutions.
- Testing platforms are updated and iterated quickly, but clinical validation lags behind. For example, new algorithms have improved the ability to identify low-level mosaicism, but translating these technical advances into accurate clinical predictions still requires more research.
Accuracy is a technical indicator, but clinical decision-making cannot rely solely on numbers. The patient’s age, previous reproductive history, number of embryos, financial costs, and psychological capacity are all factors in a comprehensive assessment.
① Patients preparing for PGT are advised to understand the accuracy boundaries of the test in advance and not to hold expectations of “absolute normality.”
② When choosing a reproductive center, focus on its annual PGT cycle count, biopsy laboratory quality control records, and genetic counseling resources, rather than just the advertised “accuracy numbers.”
③ After transferring a PGT-screened embryo, prenatal diagnosis (amniocentesis) must be completed as planned—this is the gold standard for confirming the fetal genetic status.
④ For mosaic embryos, detailed risk assessment in a genetic counseling clinic is recommended. If necessary, consider a second biopsy or a higher-resolution testing method.
This article is written based on published clinical guidelines and multi-center research data. The content is intended for medical science popularization and reference only and does not constitute personal medical advice. Please consult a reproductive medicine center for specific diagnosis and treatment plans.
Comments (0)